These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Ketek--the FDA perspective. Soreth J; Cox E; Kweder S; Jenkins J; Galson S N Engl J Med; 2007 Apr; 356(16):1675-6. PubMed ID: 17442912 [No Abstract] [Full Text] [Related]
5. Telithromycin and the FDA: implications for the future. Shlaes DM; Moellering RC Lancet Infect Dis; 2008 Feb; 8(2):83-5. PubMed ID: 18222155 [No Abstract] [Full Text] [Related]
6. Telithromycin: visual disorders, myasthenia. Case fatalities: this macrolide has a negative risk-benefit balance; its use not justified. Prescrire Int; 2008 Apr; 17(94):66. PubMed ID: 18516818 [No Abstract] [Full Text] [Related]
7. New safety information on Ketek. FDA Consum; 2006; 40(5):8. PubMed ID: 17328103 [No Abstract] [Full Text] [Related]
8. Limit Ketek to pneumonia, experts advise: advisers urge black-box warning. Young D Am J Health Syst Pharm; 2007 Jan; 64(2):124-5. PubMed ID: 17215452 [No Abstract] [Full Text] [Related]
9. Telithromycin: the perils of hasty adoption and persistence of off-label prescribing. Gleason PP; Walters C; Heaton AH; Schafer JA J Manag Care Pharm; 2007 Jun; 13(5):420-5. PubMed ID: 17605513 [TBL] [Abstract][Full Text] [Related]
11. Fraud, errors taint a key study of widely used Sanofi drug; despite some faked results, FDA approves antibiotic; one doctor's cocaine use; company defends safety. Mathews AW Wall St J (East Ed); 2006 May; ():A1, A12. PubMed ID: 16838449 [No Abstract] [Full Text] [Related]
12. Telithromycin. Raja A; Lebbos J; Kirkpatrick P Nat Rev Drug Discov; 2004 Sep; 3(9):733-4. PubMed ID: 15368658 [No Abstract] [Full Text] [Related]
13. Effective integration of medical and pharmacy claims to better protect patient safety--a long road yet to travel. Curtiss FR J Manag Care Pharm; 2007 Jun; 13(5):429-30. PubMed ID: 17605515 [No Abstract] [Full Text] [Related]
14. Telithromycin: the first ketolide antimicrobial. Nguyen M; Chung EP Clin Ther; 2005 Aug; 27(8):1144-63. PubMed ID: 16199242 [TBL] [Abstract][Full Text] [Related]
15. Excess mortality related to cefepime. Leibovici L; Yahav D; Paul M Lancet Infect Dis; 2010 May; 10(5):293-4. PubMed ID: 20417410 [No Abstract] [Full Text] [Related]
16. Telithromycin: do we really need this antimicrobial? Fish DN Am J Health Syst Pharm; 2005 May; 62(9):901. PubMed ID: 15851495 [No Abstract] [Full Text] [Related]
17. Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world. Echols RM Ann N Y Acad Sci; 2011 Dec; 1241():153-61. PubMed ID: 22191531 [TBL] [Abstract][Full Text] [Related]
18. Amoxicillin/telithromycin-induced rash in infectious mononucleosis. Wargo KA; McConnell V; Jennings M Ann Pharmacother; 2005 Sep; 39(9):1577. PubMed ID: 16046485 [No Abstract] [Full Text] [Related]
19. Telithromycin. Aventis Pharma. Johnson AP Curr Opin Investig Drugs; 2001 Dec; 2(12):1691-701. PubMed ID: 11892930 [TBL] [Abstract][Full Text] [Related]